Abstract
Prostate cancer (PC) was 5% of all revealed male malignancies in the Russian Federation in 2009. Among 23845 detected patients with PC, 53.4% had its Stage III or IV. This paper gives the results of a follow-up of patients with locally advanced and generalized PC treated by different hormonal therapy regimens. The purpose of the study was to search for the optimal hormonal therapy regimen, by maintaining the quality of life, whose criteria were potency level, libido, and normal physical activity. The follow-up data may lead to the conclusion that the 6-month use of luteinizing hormone-releasing hormone (LHRH) agonists causes an irreversible reduction in potency and libido and a considerable decrease in testosterone levels. Sustained-release LHRH agonists decrease testosterone levels (below 20 ng/dl), are an easy-to-use and simple dosage form, and may be recommended for outpatient administration.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
